Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement

E. Vrdoljak, G. Bodoky, J. Jassem, RA. Popescu, J. Mardiak, R. Pirker, T. Čufer, S. Bešlija, A. Eniu, V. Todorović, K. Kubáčková, G. Kurteva, Z. Tomašević, A. Sallaku, S. Smichkoska, Ž. Bajić, BI. Šikić,

. 2016 ; 21 (10) : 1183-1190. [pub] 20160708

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18017165

: The incidence of many cancers is higher in Western European (WE) countries, but mortality is frequently higher in Central and Eastern European (CEE) countries. A panel of oncology leaders from CEE countries participating in the South Eastern European Research Oncology Group (SEEROG) was formed in 2015, aiming to analyze the current status and trends of oncology care in CEE and to propose recommendations leading to improved care and outcomes. The SEEROG panel, meeting during the 11th Central European Oncology Congress, proposed the following: (a) national cancer control plans (NCCPs) required in all CEE countries, defining priorities in cancer care, including finance allocation considering limited health care budgets; (b) national cancer registries, describing in detail epidemiological trends; (c) efforts to strengthen comprehensive cancer centers; (d) that multidisciplinary care should be mandated by the NCCPs; (e) that smaller hospitals should be connected to multidisciplinary tumor boards via the Internet, providing access to specialized expertise; (f) nationwide primary prevention programs targeting smoking, obesity, and alcohol consumption and centrally evaluated secondary prevention programs for cervical, colorectal, and breast cancers; (g) prioritize education for all involved in cancer care, including oncology nurses, general practitioners, and palliative care providers; (h) establish outpatient care in day hospitals to reduce costs associated with the current inpatient model of care in CEE countries and to improve patients' quality of life; (i) long-term pharmacoeconomic evaluations of new therapies in CEE countries; (j) increase national oncology budgets in view of the higher mortality rates in CEE compared with WE countries; and (k) CEE countries urgently need help from the European Union to increase and monitor overall investment in cancer care. IMPLICATIONS FOR PRACTICE: Significant differences in cancer incidence and mortality have been observed between European countries. While the incidence of many cancer types is higher in Western European (WE) countries, the mortality is generally higher in Central and Eastern Europe (CEE). The primary purpose of this review was to describe the current status and trends of oncology care in the CEE region, to raise awareness among physicians, regulators, and payers, and to propose the most needed changes in order to make the oncology care in CEE closer to the WE standards.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017165
003      
CZ-PrNML
005      
20180518110308.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1634/theoncologist.2016-0137 $2 doi
035    __
$a (PubMed)27401890
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vrdoljak, Eduard $u Department of Oncology, Clinical Hospital Center Split, School of Medicine, University of Split, Split, Croatia edo.vrdoljak@gmail.com.
245    10
$a Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement / $c E. Vrdoljak, G. Bodoky, J. Jassem, RA. Popescu, J. Mardiak, R. Pirker, T. Čufer, S. Bešlija, A. Eniu, V. Todorović, K. Kubáčková, G. Kurteva, Z. Tomašević, A. Sallaku, S. Smichkoska, Ž. Bajić, BI. Šikić,
520    9_
$a : The incidence of many cancers is higher in Western European (WE) countries, but mortality is frequently higher in Central and Eastern European (CEE) countries. A panel of oncology leaders from CEE countries participating in the South Eastern European Research Oncology Group (SEEROG) was formed in 2015, aiming to analyze the current status and trends of oncology care in CEE and to propose recommendations leading to improved care and outcomes. The SEEROG panel, meeting during the 11th Central European Oncology Congress, proposed the following: (a) national cancer control plans (NCCPs) required in all CEE countries, defining priorities in cancer care, including finance allocation considering limited health care budgets; (b) national cancer registries, describing in detail epidemiological trends; (c) efforts to strengthen comprehensive cancer centers; (d) that multidisciplinary care should be mandated by the NCCPs; (e) that smaller hospitals should be connected to multidisciplinary tumor boards via the Internet, providing access to specialized expertise; (f) nationwide primary prevention programs targeting smoking, obesity, and alcohol consumption and centrally evaluated secondary prevention programs for cervical, colorectal, and breast cancers; (g) prioritize education for all involved in cancer care, including oncology nurses, general practitioners, and palliative care providers; (h) establish outpatient care in day hospitals to reduce costs associated with the current inpatient model of care in CEE countries and to improve patients' quality of life; (i) long-term pharmacoeconomic evaluations of new therapies in CEE countries; (j) increase national oncology budgets in view of the higher mortality rates in CEE compared with WE countries; and (k) CEE countries urgently need help from the European Union to increase and monitor overall investment in cancer care. IMPLICATIONS FOR PRACTICE: Significant differences in cancer incidence and mortality have been observed between European countries. While the incidence of many cancer types is higher in Western European (WE) countries, the mortality is generally higher in Central and Eastern Europe (CEE). The primary purpose of this review was to describe the current status and trends of oncology care in the CEE region, to raise awareness among physicians, regulators, and payers, and to propose the most needed changes in order to make the oncology care in CEE closer to the WE standards.
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a ekonomika farmaceutická $7 D017850
650    _2
$a Evropa $7 D005060
650    _2
$a incidence $7 D015994
650    _2
$a nádory $x epidemiologie $x etiologie $x mortalita $x prevence a kontrola $7 D009369
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bodoky, Gyorgy $u Department of Oncology, St. László Teaching Hospital, Budapest, Hungary.
700    1_
$a Jassem, Jacek $u Medical University of Gdańsk, Gdańsk, Poland.
700    1_
$a Popescu, Razvan A $u Department of Medical Oncology, Tumor Center Aarau, Aarau, Switzerland.
700    1_
$a Mardiak, Jozef $u 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic National Cancer Institute, Bratislava, Slovak Republic.
700    1_
$a Pirker, Robert $u Division of Oncology and Hematology, Department of Medicine I, Medical University of Vienna, Austria.
700    1_
$a Čufer, Tanja $u University Clinic Golnik, Golnik, Slovenia.
700    1_
$a Bešlija, Semir $u Institute of Oncology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
700    1_
$a Eniu, Alexandru $u Department of Breast Tumors, Cancer Institute "Prof. Dr. I. Chiricuta" Cluj-Napoca, Romania.
700    1_
$a Todorović, Vladimir $u Oncology and Radiotherapy Clinic, Clinical Centre of Montenegro, Podgorica, Montenegro.
700    1_
$a Kubáčková, Kateřina $u Department of Oncology, University Hospital Motol, Charles University, Prague, Czech Republic.
700    1_
$a Kurteva, Galia $u National Hospital of Oncology, Sofia, Bulgaria.
700    1_
$a Tomašević, Zorica $u Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
700    1_
$a Sallaku, Agim $u Oncology Institute, University Hospital Center Mother Teresa, Tirana, Albania.
700    1_
$a Smichkoska, Snezhana $u Institute of Radiotherapy and Oncology, Skopje, Macedonia.
700    1_
$a Bajić, Žarko $u Biometrika Healthcare Research, Zagreb, Croatia.
700    1_
$a Šikić, Branimir I $u Oncology Division, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
773    0_
$w MED00005061 $t The oncologist $x 1549-490X $g Roč. 21, č. 10 (2016), s. 1183-1190
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27401890 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180518110446 $b ABA008
999    __
$a ok $b bmc $g 1300789 $s 1014005
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 21 $c 10 $d 1183-1190 $e 20160708 $i 1549-490X $m The oncologist $n Oncologist $x MED00005061
LZP    __
$a Pubmed-20180515
Back

Find record

Citation metrics

Archiving options